Cargando…

Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsing after Autologous Transplant before Availability of CAR-T Cell Treatment

INTRODUCTION: Autologous stem cell transplantation (ASCT) following high-dose chemotherapy is applied as salvage therapy in patients with relapsed disease or as first-line consolidation in high-risk DLBCL with chemo-sensitive disease. However, the prognosis of relapsing DLBCL post-ASCT remained poor...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Matt, Stefanie, Bacher, Ulrike, Banz, Yara, Taleghani, Behrouz Mansouri, Novak, Urban, Pabst, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171206/ https://www.ncbi.nlm.nih.gov/pubmed/37180203 http://dx.doi.org/10.4084/MJHID.2023.025

Ejemplares similares

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML
por: Gurevich, Ekaterina, et al.
Publicado: (2022)

CAR T-cell therapy and critical care: A survival guide for medical emergency teams
por: Messmer, Anna S., et al.
Publicado: (2021)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
por: Nydegger, Anna, et al.
Publicado: (2021)

BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study
por: Stoffel, Tanja, et al.
Publicado: (2022)

Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation
por: Shumilov, Evgenii, et al.
Publicado: (2021)

Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study
por: Rausch, Christian, et al.
Publicado: (2022)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
por: Heini, Alexander D., et al.
Publicado: (2022)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma
por: Huwyler, Fabrizio, et al.
Publicado: (2023)

Novel Adaptive T-Cell Oncological Treatments Lead to New Challenges for Medical Emergency Teams: A 2-Year Experience From a Tertiary-Care Hospital in Switzerland
por: Messmer, Anna Sarah, et al.
Publicado: (2021)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients
por: Schnell, Bianca R., et al.
Publicado: (2019)

Humoral Responses to Repetitive Doses of COVID-19 mRNA Vaccines in Patients with CAR-T-Cell Therapy
por: Gössi, Simona, et al.
Publicado: (2022)

Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma
por: Messerli, Christian, et al.
Publicado: (2023)

Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy
por: Brechbühl, Simon, et al.
Publicado: (2021)

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
por: Shumilov, Evgenii, et al.
Publicado: (2023)

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
por: Lakomy, Tim, et al.
Publicado: (2023)

BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
por: Heini, Alexander D., et al.
Publicado: (2023)

Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology
por: Shumilov, Evgenii, et al.
Publicado: (2022)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
por: Sanoyan, Dilara Akhoundova, et al.
Publicado: (2023)

Autologous Transplantation for Older Adults with AML
por: Mueller, Beatrice U., et al.
Publicado: (2018)

Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias
por: Rebmann Chigrinova, Ekaterina, et al.
Publicado: (2022)

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy
por: Seipel, Katja, et al.
Publicado: (2023)

A case of CIDP concurrent with MGUS IgG kappa responsive to autologous stem cell transplantation
por: Colucci, Giuseppe, et al.
Publicado: (2020)

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
por: Wittibschlager, Valerie, et al.
Publicado: (2023)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML
por: Heini, Alexander D., et al.
Publicado: (2021)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021)

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
por: Farag, Sarah, et al.
Publicado: (2022)

Relapsed angioimmunoblastic T-cell lymphoma with acquired expression of CD20: a case report and review of the literature
por: Banz, Yara, et al.
Publicado: (2013)

Systemic mastocytosis with an associated hematological neoplasms: One or two entities?
por: Njue, Linet, et al.
Publicado: (2020)

Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital
por: Hort, Simon, et al.
Publicado: (2022)

An unusual pseudolymphoma in the context of necrotizing fasciitis: A case report
por: Dislich, Bastian, et al.
Publicado: (2022)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9lnpa1t678o221ve13eune2cp6